Angiectasia is a small, fragile cluster of widened blood vessels in the lining of the gastrointestinal (GI) tract that can rupture and bleed. You may also see the condition called angiodysplasia or angioectasia, and all three names refer to the same thing. These lesions are the most common vascular abnormality of the GI tract, yet most people who have them never know it because the lesions often cause no symptoms at all. When they do bleed, however, the consequences range from a slow iron drain that leaves you chronically tired to dramatic episodes of dark or bloody stool that land you in the hospital.
How Common Is Angiectasia and Who Gets It
Angiectasia is overwhelmingly a condition of older adults. A large population-based study found an overall prevalence of about 0.09 percent, but that number climbs steeply with age: roughly 85 to 88 percent of cases in both the upper and lower GI tract were diagnosed in people aged 60 or older, with prevalence peaking at about 0.37 percent in the 71-to-80 age group.1PubMed. Epidemiology and risk factors for angiodysplasias of the upper and lower gastrointestinal tract: A large population-based study In younger adults, angiectasia is uncommon and, when found, tends to prompt a closer look for an underlying condition driving its formation.
Men and women develop the lesions at similar rates. Because the prevalence is low in any single age bracket, many cases are discovered incidentally during endoscopy performed for another reason. The person may have gone in for a colonoscopy screening and come out with an incidental mention of a few tiny vascular spots that the gastroenterologist noted but judged harmless.
Where in the GI Tract Do These Lesions Appear
Angiectasias can show up anywhere along the digestive tube, from the stomach to the colon. One study of a Western population found the jejunum (the middle portion of the small intestine) was the most frequent location at 80 percent, followed by the duodenum at 51 percent, the stomach at about 23 percent, and the right colon at roughly 11 percent.2PubMed Central. Distribution of bleeding gastrointestinal angioectasias in a Western population About 60 percent of those patients had lesions in more than one location, which matters because having multiple lesions in different spots makes diagnosis and treatment planning harder.
The distribution is worth knowing because it affects which diagnostic tool your doctor reaches for first. Lesions in the stomach, duodenum, or colon can usually be seen with a standard upper endoscopy or colonoscopy. The small bowel, especially the jejunum, is trickier to examine and often requires specialized approaches like capsule endoscopy or balloon-assisted enteroscopy.
What Causes Blood Vessels to Widen Like This
The exact mechanism is still debated, but the leading theory centers on chronic, low-grade obstruction of the small veins in the bowel wall. The muscular layer of the GI tract contracts regularly as part of normal digestion. Over decades, those contractions can intermittently compress the tiny veins that drain blood from the inner lining. The repeated compression eventually causes those veins, along with the smaller vessels feeding into them, to stretch and become tortuous. The result is a tangle of thin-walled, dilated vessels sitting just beneath the surface of the mucosa, prone to leaking or rupturing.
This mechanical explanation accounts for why angiectasia is so much more common in older people: the cumulative wear and tear simply takes time. It also helps explain the preference for the right colon and the small bowel, where the bowel wall is thinner and the veins are more susceptible to compression.
A second layer of biology involves von Willebrand factor (VWF), a protein best known for its role in blood clotting. VWF also turns out to interact with molecules that regulate blood vessel growth, including growth factors and proteins on the surface of endothelial cells that line vessel walls. When VWF is absent or abnormal, the balance between keeping existing vessels stable and sprouting new ones tips toward unregulated vessel formation. Research has mapped out several molecular pathways through which VWF helps maintain vascular stability, but the full picture remains incomplete.3Haematologica. von Willebrand disease and angiodysplasia: a wider view of pathogenesis in pursuit of therapy This connection between VWF and vessel stability is what ties angiectasia to several systemic diseases.
Conditions That Raise the Risk
Several chronic illnesses are linked to a higher chance of developing angiectasia or to more severe bleeding when the lesions are present. Understanding these associations matters because treating the underlying condition can sometimes reduce bleeding episodes.
Aortic Stenosis and Heyde Syndrome
Heyde syndrome is the triad of aortic stenosis (a narrowed aortic valve in the heart), GI angiodysplasia with bleeding, and an acquired form of von Willebrand syndrome.4PubMed Central. Aortic stenosis and Heyde’s syndrome: A comprehensive review The connection is counterintuitive at first: how does a heart valve problem cause intestinal bleeding? The answer is mechanical. Blood forced through the narrowed valve experiences extremely high shear stress, which activates an enzyme that chops up the large, sticky multimers of von Willebrand factor. Without those large multimers, your clotting system loses one of its key tools for plugging small vessel leaks.5CMAJ. Heyde syndrome: gastrointestinal bleeding and aortic stenosis The result is that any preexisting angiectasia in the gut becomes far more likely to bleed, and bleeding is harder to stop. Replacing the aortic valve often resolves the clotting defect, and many patients see their GI bleeding improve or stop entirely after surgery.
Chronic Kidney Disease
People with chronic kidney disease (CKD) have a higher risk of both GI bleeding in general and angiodysplasia in particular compared with the general population.6PubMed Central. Diagnostic and therapeutic considerations for obscure gastrointestinal bleeding in patients with chronic kidney disease CKD disrupts platelet function and can alter the lining of blood vessels, creating a double hit: the lesions may be more likely to form and, once present, are more prone to bleed. For CKD patients on dialysis, the use of blood thinners during dialysis sessions adds yet another layer of bleeding risk.
Liver Disease and Portal Hypertension
Liver cirrhosis creates a specific variant called gastric antral vascular ectasia, or GAVE, often described as “watermelon stomach” because of the distinctive red-striped pattern visible during endoscopy. While GAVE can occur alongside portal hypertension (high blood pressure in the liver’s blood supply), research suggests that it is driven more by liver dysfunction itself than by the elevated portal pressures.7PubMed Central. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension GAVE can also appear in patients without liver disease at all.8PubMed Central. Management of gastropathy and gastric vascular ectasia in portal hypertension This distinction matters clinically because GAVE responds to endoscopic treatment, whereas portal hypertensive gastropathy, a separate condition that looks similar on endoscopy, typically requires lowering portal pressures with medication or a shunt procedure.
Von Willebrand Disease and Hereditary Hemorrhagic Telangiectasia
People born with von Willebrand disease, the most common inherited bleeding disorder, are predisposed to developing angiodysplasia because their baseline VWF levels are already low. The same pathway that underlies Heyde syndrome is at work here, just without the heart valve problem. Hereditary hemorrhagic telangiectasia (HHT) is a separate genetic condition in which fragile, abnormal blood vessels form throughout the body, including in the GI tract. Although HHT lesions are not identical to angiectasia in cause, they share enough visual and clinical features that they often appear in the same differential diagnosis and respond to some of the same treatments.
Symptoms and How Angiectasia Is Discovered
Many angiectasias cause no symptoms. When they do bleed, the presentation depends on how fast and how much blood is lost:
- Iron-deficiency anemia: The most common scenario. A slow ooze from one or more lesions drains iron stores over weeks or months. You may feel fatigued, short of breath with mild exertion, or lightheaded before anyone thinks to look at the gut.
- Melena: Dark, tarry stools that signal bleeding somewhere in the upper GI tract or small bowel. This is often what prompts a hospital visit.
- Hematochezia: Bright red blood in or on the stool, more typical when the bleeding source is in the colon.
- Obscure GI bleeding: Recurrent anemia or positive stool blood tests without a source found on initial upper endoscopy and colonoscopy. Because angiectasias in the small bowel hide between the reach of standard scopes, they are one of the leading causes of this frustrating diagnostic category.
Angiectasia rarely causes pain. The bleeding is painless, which is part of why it can go unnoticed for so long. In a patient over 60 who keeps turning up anemic despite iron supplements, GI angiectasia is high on the list of suspects.
How Doctors Find the Lesions
Finding angiectasia depends on where in the GI tract it sits and whether it is actively bleeding at the time of the exam.
Standard upper endoscopy and colonoscopy are the first-line tools for the upper GI tract and colon. Angiectasias look like small, flat, cherry-red patches or fern-like clusters of vessels, usually a few millimeters across. The challenge is the small bowel, which sits beyond the reach of conventional scopes. For that, capsule endoscopy, where you swallow a pill-sized camera that takes thousands of photographs as it travels through the gut, is a go-to option. Capsule endoscopy is noninvasive and works well in patients who are not actively hemorrhaging. It has been shown to be better than CT scans at detecting mucosal lesions like angiectasias and has a higher overall diagnostic yield for obscure bleeding.9PubMed Central. Obscure gastrointestinal bleeding: diagnostic performance of 64-section multiphase CT enterography and CT angiography compared with capsule endoscopy It is considered ideal for patients who are hemodynamically stable and do not have a bowel obstruction.10PubMed Central. Management of small bowel angioectasias diagnosed during video capsule endoscopy
When capsule endoscopy identifies a lesion that needs treatment, or when the patient is bleeding too briskly for a capsule study, balloon-assisted enteroscopy allows a gastroenterologist to physically reach deep into the small bowel, visualize lesions, and treat them in the same session. CT enterography with contrast enhancement is another option, particularly useful for ruling out arterial lesions that carry a higher bleeding risk. One case series demonstrated that multi-detector CT enterography can detect jejunal angiodysplasia that was previously identified only by conventional angiography.11PubMed Central. Multi-Detector CT Enterography to detect jejunal angiodysplasia: challenging cause of gastrointestinal bleeding Traditional catheter-based angiography, where dye is injected directly into the arteries supplying the gut, remains the gold standard for pinpointing active bleeding but is more invasive and is usually reserved for acute situations.
Telling Angiectasia Apart From Other Vascular Lesions
Not every red spot in the GI tract is an angiectasia. Several other vascular abnormalities can look similar on endoscopy but behave differently and require different management. Angiectasias are venous lesions, meaning they involve low-pressure vessels. They tend to bleed slowly and present as a chronic problem. Dieulafoy lesions and arteriovenous malformations (AVMs) are arterial lesions and carry a much higher risk of sudden, life-threatening hemorrhage.12PubMed Central. Diagnosis and therapeutic strategies for small bowel vascular lesions Dieulafoy lesions are typically managed with mechanical clips because cauterization alone has a high rebleeding rate, while large AVMs in the small bowel often need surgical removal because endoscopic treatments struggle to fully ablate them.
This distinction is why characterizing the type of vascular lesion matters, even if the initial symptoms look the same. A patient presenting with obscure GI bleeding who is found to have multiple small, flat cherry-red spots is in a very different risk category from one who has a single large pulsating vessel or a mass of tangled arteries and veins.
Endoscopic Treatment
When angiectasias are accessible by endoscopy and actively bleeding or judged likely to rebleed, the most widely used treatment is argon plasma coagulation (APC). This technique uses a jet of ionized argon gas to deliver heat to the surface of the lesion without directly touching the tissue. It works well for angiectasia: the thin-walled vessels seal off, and the surrounding tissue sustains minimal damage. APC is considered safe and effective for angiodysplasia bleeding, and its results are better for angiodysplasia than for GAVE, which tends to have a higher recurrence rate and may need multiple treatment sessions.13PubMed Central. Comparison of argon plasma coagulation in management of upper gastrointestinal angiodysplasia and gastric antral vascular ectasia hemorrhage
Newer approaches include radiofrequency ablation (RFA) delivered through an enteroscope. An RFA catheter covers a wider area of intestinal lining per treatment pass, which is useful when there are many small lesions scattered across a long segment of bowel.14VideoGIE. Multicenter case series of patients with small-bowel angiodysplasias treated with a small-bowel radiofrequency ablation catheter Other endoscopic options include bipolar electrocoagulation and contact thermal probes, though APC has become the dominant choice in most centers.
Medications for Recurrent Bleeding
Not every patient is a candidate for endoscopic treatment. Some have too many lesions scattered across the small bowel. Others rebleed despite repeated cauterization sessions. For these patients, drug therapy aims to reduce the frequency and severity of bleeding episodes.
Octreotide, a synthetic version of the hormone somatostatin, has the most clinical experience behind it. It works through several mechanisms: reducing blood flow to the gut, promoting platelet clumping, and suppressing the growth of new abnormal vessels.15PubMed Central. Role of octreotide in small bowel bleeding In patients with refractory angiodysplasia bleeding, octreotide has been shown to reduce the number of bleeding episodes, hospitalizations, and blood transfusion requirements, even in patients who must continue taking blood thinners.16PubMed. Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by diffuse angiodysplasia in a patient on anticoagulation therapy It is given as a monthly injection (the long-acting form) or subcutaneously several times a day, and it can be used for months to years if needed.
Thalidomide, a drug with a notorious history but a genuine anti-angiogenic effect, has been explored for angiodysplasia that does not respond to other treatments. By blocking the formation of new blood vessels, thalidomide can shrink existing lesions and reduce bleeding. Case reports describe temporary control of GI bleeding with daily oral doses, including in patients with underlying bleeding disorders.17PubMed Central. Thalidomide for the Treatment of Gastrointestinal Bleeding Due to Angiodysplasia in a Patient with Glanzmann’s Thrombasthenia However, thalidomide carries significant side effects, including nerve damage and the well-known risk of severe birth defects, so it is strictly limited to patients who have exhausted other options and who are not pregnant or planning pregnancy.
Bevacizumab, an anti-VEGF antibody widely used in cancer therapy, has shown promising early results for vascular lesions that resist standard treatment. Small studies have reported reductions in bleeding symptoms and, in some cases, visible shrinkage of the lesions.18Frontiers in Gastroenterology. Role of thalidomide in angiodysplasia-related gastrointestinal bleeding: a systematic review The evidence base is still thin, and the drug is expensive and requires intravenous infusion, so it remains a last-resort option.
Rebleeding and Long-Term Outlook
One of the most frustrating features of angiectasia is its tendency to come back. Even after successful endoscopic treatment, new lesions can form or existing ones can reopen. In one study tracking patients with small-bowel angiectasia over a median follow-up of about two and a half years, roughly a third experienced rebleeding. The strongest predictor of rebleeding was having three or more lesions at diagnosis, which carried nearly four times the odds of recurrence compared with having fewer lesions. The trend toward lower rebleeding in patients who received endoscopic treatment did not reach statistical significance, and for the majority of those who did rebleed, the bleeding was ultimately brought under control by the end of follow-up.19PubMed Central. Frequency and risk factors for rebleeding events in patients with small bowel angioectasia
This rebleeding pattern shapes how doctors approach the condition. Rather than expecting a one-and-done cure, the goal is often to manage bleeding over time through a combination of endoscopic retreatment when feasible, iron supplementation or transfusions to keep up with losses, and pharmacotherapy for patients who continue to bleed. For the subset of patients with aortic stenosis, valve replacement can be a turning point by correcting the acquired von Willebrand defect that worsens bleeding.
When Surgery Becomes Necessary
Surgery for angiectasia is uncommon today, reserved for patients who bleed severely despite repeated endoscopic and medical therapy, or for those with a clearly localized source of major hemorrhage. The usual operation is resection of the segment of bowel containing the offending lesions. Because angiectasias are often multiple and spread across different regions, surgery alone does not guarantee an end to bleeding, and new lesions can appear in the remaining bowel. For patients with GAVE that fails endoscopic treatment, antrectomy (removal of the lower part of the stomach) has been performed with good results, though this is a major operation with its own risks and long-term consequences for digestion.
Living With Angiectasia on Blood Thinners
A large number of angiectasia patients are also on anticoagulants or antiplatelet drugs for heart disease, atrial fibrillation, or mechanical heart valves. This creates a genuine clinical dilemma. Stopping blood thinners reduces GI bleeding risk but raises the risk of stroke or clotting. Continuing them keeps the cardiovascular benefit but may perpetuate bleeding that is already hard to control. There is no universal answer. The decision involves weighing the severity and frequency of bleeding episodes against the patient’s specific cardiovascular risk, often with input from both a gastroenterologist and a cardiologist.
Octreotide has proven useful in this context specifically because it can reduce bleeding episodes without requiring the patient to stop anticoagulant therapy. For patients on warfarin or newer direct oral anticoagulants who keep presenting with anemia or melena, adding octreotide and continuing the blood thinner is sometimes the least bad option. Iron infusions can also help keep hemoglobin levels acceptable while the underlying lesions are managed.